![Vedolizumab for Inflammatory Bowel Disease: two year results of the ICC Registry, a nationwide prospective observational cohort study]()
Vedolizumab for Inflammatory Bowel Disease: two year results of the ICC Registry, a nationwide prospective observational cohort studyBiemans, Vince B.C.; van der Woude, Janneke; Dijkstra, Gerard; van der Meulen‐de Jong, Andrea E.; Oldenburg, Bas; de Boer, Nanne K.H.; Löwenberg, Mark; Srivastava, Nidhi; Bodelier, Alexander G.L.; West, Rachel; Jansen, Jeroen M.; de Vries, Annemarie C.; Haans, Jeoffrey J.L.; de Jong, Dirk J.; Pierik, Marie J.; Hoentjen, Frank; van der Woude, Janneke; Dijkstra, Gerard; van der Meulen ‐ de Jong, Andrea E.; Oldenburg, Bas; de Boer, Nanne K.H.; Löwenberg, Mark; Bodelier, Alexander G.L.; West, Rachel; Jansen, Jeroen M.; de Vries, Annemarie C.; Haans, Jeoffrey J.L.; de Jong, Dirk J.; Pierik, Marie J.; Hoentjen, Frank · Clinical Pharmacology & Therapeutics · 2019